GlassScriptPhysician profile
Basel Skeif
NPI 1003090390
$6,714.53
in general payments reported to CMS, 2019-2025
35 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $819 · 2021: $632 · 2022: $998 · 2023: $1,299 · 2024: $879 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,033.65 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $718.09 | 2019-2025 | Lifevest |
| Amgen INC. | $675.11 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $610.27 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $429.81 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Abbott Laboratories | $349.24 | 2019-2024 | Gallant, Assurity, Cardiomems |
| Kestra Medical Technology Services, INC. | $273.69 | 2022-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.99 | 2019-2025 | Jardiance |
| Abiomed | $249.62 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $234.68 | 2019-2023 | Livalo, Seglentis |
| Pfizer INC. | $173.83 | 2019-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $157.03 | 2021-2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $152.15 | 2019-2024 | Xarelto |
| Cvrx, INC. | $139.58 | 2024-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $134.64 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.69 | 2024-2025 | Ozempic |
| Zoll Respicardia, INC. | $125.21 | 2021 | |
| Esperion Therapeutics, INC. | $99.71 | 2020-2022 | |
| Amarin Pharma, INC. | $91.61 | 2019-2021 | |
| Baxter Healthcare | $83.95 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $72.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.79 | 2022-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $64.05 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $61.18 | 2019-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $56.70 | 2022-2024 | Opsumit |
| Boston Scientific Corporation | $52.58 | 2019-2023 | Watchman Access System |
| Arbor Pharmaceuticals, INC. | $45.87 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $30.24 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $26.12 | 2025 | Attruby |
| Medtronic Vascular, INC. | $25.28 | 2020 | |
| Bardy Diagnostics, INC. | $25.00 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.28 | 2022 | |
| Biotronik INC. | $17.16 | 2021 | |
| Ge Healthcare | $16.37 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.88 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Skeif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.